查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1926876

体外震波治疗设备市场（按设备类型、应用和最终用户划分）－2026-2032年全球预测

Extracorporeal Shock Wave Therapy Device Market by Device Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年体外震波治疗设备市场价值为 2.272 亿美元，预计到 2026 年将成长至 2.5916 亿美元，复合年增长率为 14.41%，到 2032 年将达到 5.832 亿美元。

关键市场统计数据
基准年 2025 2.272亿美元
预计年份：2026年 2.5916亿美元
预测年份 2032 5.832亿美元
复合年增长率 (%) 14.41%

体外震波疗法简明概述：阐述临床预期、商业性驱动因素以及医疗保健领导者的决策要点

体外震波疗法已从一种小众治疗方法发展成为一种用途广泛的治疗治疗方法，可应用于包括美容、肌肉骨骼、心臟病学和泌尿系统在内的众多临床领域。近年来，临床医生和采购团队日益认识到该技术作为一种非侵入性或微创替代传统外科治疗方法的潜力，从而带动了医院、专科诊所和復健中心的需求。随着临床应用的普及，技术的改进和各种设备配置的出现，拓展了临床医生可选择的治疗方案，实现了更精准的能量传输和针对特定应用通讯协定的治疗方案。

不断变化的临床适应症、技术进步和治疗模式创新如何重塑衝击波疗法的竞争格局和推广路径

体外震波治疗领域正经历变革性的转变，这得益于临床、技术和治疗模式创新的融合。在临床方面，除传统碎石和足底筋膜炎外，体外震波治疗适应症的不断拓展，推动了人们对美容应用、复杂整形外科修復以及某些心臟病病例的兴趣。这种临床应用的多样化正在改变购买者对设备的评估方式，促使他们更加关注能够支持多种适应症通讯协定的系统以及可减少多次资本投资的模组化配件。

为评估 2025 年生效的关税对供应链和采购带来的压力，製造商和供应商被迫重新评估其采购、定价和证据策略。

计划于2025年生效的针对特定医疗设备进口的关税，使得供应链韧性和筹资策略的重要性日益凸显。即使关税仅针对零件或成品，製造商和经销商在定价、采购和合约承诺方面也将面临更大的复杂性。事实上，关税将推高设备及配件的总到岸成本，进而影响预算紧张的医院、专科诊所和物理治疗中心的采购週期。

细分市场分析洞察：设备架构、临床适应症亚群和最终用户操作需求如何交织，进而影响市场采纳趋势和产品策略

清楚了解器材和适应症的细分有助于产品设计、临床开发和上市计划。根据器械类型，聚焦式和放射式技术具有不同的临床和商业性特性。聚焦式器械可输送深层能量，通常优先用于需要靶向组织穿透的适应症。而放射式系统则将能量浅层分布，常用于各种肌肉骨骼治疗和美容通讯协定。按应用领域划分，市场涵盖美容、心臟病学、整形外科和泌尿系统。在美容领域，减少橘皮组织和治疗疤痕是热门话题，这两个都需要持续、可靠的美容效果、高效的工作流程和可预测的患者满意度指标。在心臟病学领域，适应症包括心肌缺血和难治性心绞痛，由于需要可靠的临床终点指标和整合到心臟护理路径中，这两项都存在较高的进入门槛。在整形外科领域，治疗方法分为足底筋膜炎、肩迴旋肌损伤和网球肘，从业人员优先考虑器械的易用性、手术时间和可重复的临床通讯协定。在泌尿系统领域，治疗方法包括勃起功能障碍和肾结石治疗，这些领域代表了具有不同监管要求和报销预期的临床群体。就最终用户而言，医疗设备必须满足医院、整形外科诊所和物理治疗中心的实际营运需求。医院需要能够与复杂的诊疗流程整合并满足严格的消毒和维护要求的设备，而整形外科诊所则优先考虑快速的门诊手术流程和医生的偏好。物理治疗中心需要经济高效、易于操作的系统，以辅助保守治疗并支持可衡量的功能改善。整合这些细分层面，可以揭示临床需求、产品特性和购买行为之间的交集，从而突出製造商针对特定器械类型、适应症和最终用户组合的优先发展机会，以最大限度地提高临床影响和商业性吸引力。

区域监管差异、支付方趋势和医疗服务模式将如何决定优先的打入市场策略和特定区域的证据需求？

区域特征会影响监管时间表、支付方预期和临床实践模式，进而影响企业的市场推广重点和资源分配。在美洲地区，门诊手术量大，且医疗融资环境鼓励在产品展现明确价值时进行创新，这些因素往往能够推动临床接受度。医疗服务模式从医院向门诊和诊所的转变，为注重效率和易用性的医疗设备创造了机会，而当地的报销政策也倾向于那些能够切实降低后续成本的干预措施。

为什么临床可靠性、卓越的服务和策略伙伴关係关係对于寻求在衝击波治疗领域获得可持续竞争优势的公司至关重要

在体外震波治疗领域，竞争优势越来越取决于企业能否将临床可靠性与营运关键的产品特性结合。领导企业透过整合取得专利的能量输送系统、全面的培训和服务项目以及基于价值的商业模式来降低采用者门槛，从而脱颖而出。与临床意见领袖和早期应用中心建立策略伙伴关係仍然是建立循证基础的核心，而循证基础对于获得更广泛的支付方认可和临床医生支持至关重要。

为确保临床应用和商业性成功，经营团队可采取实际行动，透过数据利用、灵活的商业化以及遵守当地法规来实现这一目标。

产业领导者应优先采取切实可行的措施，将洞见转化为可衡量的进展。首先，加快收集目标适应症和终端用户环境中的真实世界临床结果数据，以支持产品价值主张并与支付者沟通。高品质的註册研究和前瞻性观察性研究能够弥合临床试验与常规实践之间的差距，及时提供证据，从而在预算有限的环境下证明其可行性。其次，投资于模组化产品架构，使其能够在单一平台上支援多种应用，从而减轻医院和门诊诊所的采购负担，同时最大限度地提高整个医疗团队的利用率。

采用严谨的多源调查方法，结合临床文献、临床医师访谈、供应商分析和政策审查，得出可操作且检验的研究结果。

本研究采用多层次调查方法，结合一级资讯来源和二级资讯来源，结构严谨，旨在确保研究的广度和深度。研究首先对同侪审查的临床文献、会议报告和监管文件进行全面回顾，按适应症梳理证据并确定关键绩效指标。一手研究包括对医院、整形外科诊所和物理治疗中心的临床医生进行结构化访谈，以了解最终用户的偏好、操作流程和应用障碍。这些访谈为理解设备功能如何在实际临床环境中转化为实际应用价值提供了背景资讯。

汇聚的策略要务表明，产品设计、证据产生和商业性敏捷性的协调一致将决定长期实施的成功。

总之，体外震波疗法正处于一个转折点，临床多样化、设计创新和采购行为的转变交汇融合，既带来了巨大的机会，也带来了实际挑战。能够将卓越的技术与对终端使用者工作流程和区域监管现实的深刻理解相结合的机构，将更有机会取得成功。那些能够建立可靠的真实世界数据、设计支援多种适应症的模组化平台并提供灵活商业条款的公司，将最有利于加速体外震波疗法在医院、整形外科诊所和物理治疗中心的推广应用。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 体外震波治疗设备市场（依设备类型划分）

  • 专注型
  • 径向

第九章 体外震波治疗设备市场（依应用领域划分）

  • 美丽
    • 减少橘皮组织
    • 疤痕治疗
  • 心臟病学
    • 心肌缺血
    • 难治性心绞痛
  • 整形外科
    • 足底筋膜炎
    • 肩迴旋肌损伤
    • 网球肘
  • 泌尿系统
    • 勃起功能障碍
    • 肾结石治疗

第十章 体外震波治疗设备市场（依最终用户划分）

  • 医院
  • 整形外科诊所
  • 物理治疗中心

第十一章 体外震波治疗设备市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 体外震波治疗设备市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 各国体外震波治疗设备市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国体外震波治疗设备市场

第十五章 中国体外震波治疗设备市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • BTL Industries
  • Dornier MedTech
  • EMS Electro Medical Systems
  • Guangzhou Longest Science & Technology
  • Gymna
  • Inceler Medikal
  • LIKAMED GmbH
  • MTS Medical
  • Richard Wolf GmbH
  • Storz Medical AG
  • Tissue Regeneration Technologies
  • Zimmer MedizinSysteme
Product Code: MRR-4F7A6D4FF34E

The Extracorporeal Shock Wave Therapy Device Market was valued at USD 227.20 million in 2025 and is projected to grow to USD 259.16 million in 2026, with a CAGR of 14.41%, reaching USD 583.20 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 227.20 million
Estimated Year [2026] USD 259.16 million
Forecast Year [2032] USD 583.20 million
CAGR (%) 14.41%

A concise orientation to extracorporeal shock wave therapy that outlines clinical promise, commercial drivers, and decision imperatives for healthcare leaders

Extracorporeal shock wave therapy has transitioned from a niche intervention to a clinically versatile modality applied across aesthetic, musculoskeletal, cardiology, and urology contexts. Over recent years, clinicians and procurement teams have increasingly recognized the technique's potential to offer non-invasive or minimally invasive alternatives to traditional surgical pathways, thereby creating demand among hospitals, specialty clinics, and rehabilitation centers. Alongside clinical adoption, engineering refinements and varying device architectures have broadened the therapeutic envelope available to practitioners, enabling more precise energy delivery and application-specific protocols.

Consequently, stakeholders must appreciate both the clinical evidence base and the commercial mechanics that enable or constrain adoption. Payers and health systems evaluate therapies through lenses of clinical efficacy, cost-effectiveness, and operational integration, while device manufacturers contend with design choices that influence capital expenditure, training burden, and consumable requirements. From a strategic perspective, understanding these intersecting pressures is essential to designing product roadmaps, clinical trials, and market access strategies that align with provider workflows and reimbursement realities.

Moving forward, the introduction frames the report's intent: to synthesize clinical trends, device differentiation, end-user requirements, and external policy drivers so that executives and clinical leaders can make informed decisions about investment, deployment, and partnership opportunities in extracorporeal shock wave therapy.

How evolving clinical indications, technological advances, and delivery model innovation are reshaping competitive dynamics and adoption pathways in shock wave therapy

The therapeutic landscape for extracorporeal shock wave therapy is experiencing transformative shifts driven by converging clinical, technological, and delivery-model innovations. Clinically, expanding evidence for indications beyond traditional stone fragmentation and plantar fasciitis has elevated interest in aesthetic applications, complex orthopedic repairs, and select cardiology use-cases. This clinical diversification changes how purchasers evaluate devices, pushing emphasis toward systems that can support multi-indication protocols and modular accessories that reduce the need for multiple capital purchases.

Technologically, advances in energy modulation, ergonomic probe design, and integrated imaging or guidance tools permit more targeted treatments and improved patient comfort. These advancements systematically lower barriers to adoption within outpatient and clinic settings by reducing procedure time and complication risk. At the same time, digital integration and data capture capabilities are enabling performance analytics and outcome tracking that payers increasingly demand to justify coverage and reimbursement.

From a delivery perspective, shifting care toward ambulatory surgery centers and specialized physiotherapy centers encourages manufacturers to design compact, portable systems suited to lower-acuity settings. In parallel, new commercial models, including flexible leasing and service bundle offerings, are realigning procurement decisions and enabling faster deployment. Taken together, these trends signify a landscape in which clinical versatility, ease of use, and data-driven outcomes increasingly determine competitive standing and long-term adoption trajectories.

Assessing the 2025 tariff-induced supply chain and procurement pressures that compel manufacturers and providers to rethink sourcing, pricing, and evidence strategies

Recent tariff measures announced for 2025 affecting certain medical device imports have created an environment in which supply chain resilience and procurement strategy require heightened attention. Even when tariffs apply to a subset of components or finished devices, manufacturers and distributors face increased complexity in pricing, sourcing, and contractual commitments. In practice, tariffs can amplify the total landed cost of devices and accessories, which in turn influences procurement cycles at hospitals, specialty clinics, and physiotherapy centers that operate under constrained capital budgets.

Manufacturers often respond by localizing production, reevaluating supplier relationships, or redesigning product architectures to substitute tariff-exposed components. Such adjustments can be strategically beneficial but demand upfront investment and a robust change management plan. Meanwhile, distributors and purchasing organizations have to reconcile longer lead times and potential cost variability with the need to maintain stable supply for clinical programs. Longer term, procurement teams may prioritize suppliers that demonstrate diversified manufacturing footprints or transparent cost pass-through mechanisms.

Moreover, tariffs can alter commercial conversations with payers and providers by increasing the emphasis on total cost of care and measurable outcomes. Stakeholders are likely to demand stronger evidence of clinical benefit and cost-offsets in light of higher device acquisition costs. Consequently, companies should prioritize post-market data collection and health economic analyses that demonstrate value in real-world settings. By doing so, organizations mitigate tariff-induced headwinds and position themselves as reliable partners for health systems navigating budgetary constraints.

Segment-driven insights revealing how device architecture, clinical indication subgroups, and end-user operational needs intersect to shape adoption and product strategy

A clear understanding of device and application segmentation informs product design, clinical development, and go-to-market planning. Based on device type, the clinical and commercial profiles diverge between Focused and Radial technologies; Focused devices concentrate energy at depth and are often prioritized for indications requiring targeted tissue penetration, whereas Radial systems disperse energy superficially and are commonly selected for diffuse musculoskeletal or aesthetic protocols. Based on application, the market spans Aesthetic, Cardiology, Orthopedic, and Urology uses. Within Aesthetic practice, attention centers on cellulite reduction and scar treatment, each demanding proof of consistent cosmetic outcomes, streamlined workflows, and predictable patient satisfaction metrics. Within Cardiology, indications include myocardial ischemia and refractory angina, both of which carry high barriers to adoption due to the need for robust clinical endpoints and integration with cardiac care pathways. Orthopedic applications break down into plantar fasciitis, rotator cuff injury, and tennis elbow, where practitioners emphasize device ergonomics, procedure time, and reproducible clinical protocols. Urology applications include erectile dysfunction and kidney stone treatment, representing distinct clinical communities with differing regulatory and reimbursement expectations. Based on end user, devices must address the operational realities of Hospitals, Orthopedic Clinics, and Physiotherapy Centers. Hospitals demand devices that integrate with complex care pathways and meet stringent sterilization and service requirements, while orthopedic clinics prioritize devices that enable rapid throughput of ambulatory procedures and strong physician preference. Physiotherapy centers look for cost-effective, easy-to-operate systems that augment conservative care and support measurable functional improvements. Integrating these segmentation layers reveals where clinical demand, product features, and purchasing behavior intersect, and it highlights prioritization opportunities for manufacturers targeting specific combinations of device type, application, and end user to maximize clinical impact and commercial traction.

How nuanced regional differences in regulation, payer dynamics, and care delivery models determine prioritized market entry strategies and localized evidence needs

Regional dynamics influence regulatory timelines, payer expectations, and clinical practice patterns, thereby shaping how companies prioritize market entry and resource allocation. In the Americas, clinical acceptance is often driven by strong procedural volumes in outpatient centers and a healthcare financing environment that can support innovation when clear value is demonstrated. Transitioning from hospital-centric care to ambulatory and clinic-based treatment settings has created opportunities for devices designed for throughput and ease of use, and local reimbursement policies favor interventions with tangible reductions in downstream costs.

Across Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable payer models create a need for regionally tailored evidence packages and commercial approaches. In some European markets, centralized health technology assessment mechanisms require robust comparative-effectiveness data, while other jurisdictions emphasize cost containment and clinician-led adoption. Middle Eastern and African markets may prioritize different product attributes, such as ease of maintenance and total cost of ownership, given varying infrastructure constraints.

In the Asia-Pacific region, rapid expansion of private specialty clinics and increasing investment in non-invasive therapeutic modalities fuel interest in shock wave devices. Regulatory regimes are evolving to balance innovation and safety, and local manufacturing or distribution partnerships are frequently advantageous. Additionally, cultural and practice-pattern differences influence which applications gain early traction, underscoring the need for localized clinical studies and culturally attuned marketing strategies. Across all regions, a nuanced combination of regulatory preparedness, evidence generation, and channel partnerships will determine success.

Why clinical credibility, service excellence, and strategic partnerships are decisive for firms seeking durable competitive advantage in shock wave therapy

Competitive positioning within the extracorporeal shock wave therapy space increasingly depends on a company's ability to combine clinical credibility with operationally relevant product features. Leaders differentiate through a mix of patented energy delivery systems, comprehensive training and service programs, and value-based commercial models that reduce friction for adopters. Strategic partnerships with clinical opinion leaders and early adoption sites remain central to building the evidence base required for broader payer acceptance and clinician endorsement.

Beyond core technology, after-sales support and clinical education are decisive factors for many purchasers, particularly in high-volume hospitals and specialty clinics. Companies that offer structured training curricula, outcome-tracking platforms, and field service agreements reduce perceived risk and accelerate the transition from trial use to routine clinical deployment. In parallel, organizations investing in digital tools for documentation and remote monitoring are better positioned to capture real-world outcomes that inform reimbursement discussions and continuous product improvement.

Mergers and alliances continue to reshape competitive dynamics as larger medical device companies seek to add complementary energy-based therapies to their portfolios and specialist manufacturers pursue scale or distribution reach. For smaller innovators, focused indication strategies and nimble regulatory approaches can create pathways to differentiation. Ultimately, the combination of technology robustness, service excellence, and evidence generation capacity determines whether a firm secures meaningful clinical penetration and long-term revenue stability.

Practical actions for executives to secure clinical adoption and commercial traction through data, flexible commercialization, and localized regulatory alignment

Industry leaders should prioritize a set of actionable moves that translate insight into measurable progress. First, accelerate collection of real-world outcome data across targeted indications and end-user settings to substantiate value claims and support payer conversations. High-quality registries and prospective observational studies can bridge gaps between clinical trials and everyday practice, offering timely evidence to justify adoption in budget-constrained environments. Second, invest in modular product architectures that enable a single platform to address multiple applications, thereby reducing the procurement burden on hospitals and outpatient centers while maximizing utilization across care teams.

Third, reconfigure commercial models to align with provider cash-flow realities by offering flexible procurement options such as leasing, pay-per-use, or bundled service agreements. Such models can lower upfront barriers and encourage broader device trialing. Fourth, strengthen regional regulatory and distribution strategies by cultivating local partnerships that expedite market entry and accommodate jurisdictional evidence requirements. Fifth, design education and support programs that reduce clinical variability and ensure consistent procedural quality; this includes training for physicians, technicians, and administrative staff along with standardized outcome measurement protocols.

Implementing these recommendations requires cross-functional coordination across clinical affairs, regulatory, commercial, and supply chain teams. By aligning organizational incentives around clear clinical outcomes and provider-centric value propositions, companies can accelerate adoption while mitigating external pressures such as tariff volatility and evolving payer expectations.

A rigorous multi-source methodology blending clinical literature, clinician interviews, vendor analysis, and policy review to produce actionable, validated insights

The research employed a multi-tiered methodology combining primary and secondary sources, structured to ensure both breadth and depth of insight. The approach began with a comprehensive review of peer-reviewed clinical literature, conference proceedings, and regulatory filings to map indication-specific evidence and identify key performance metrics. Primary research included structured interviews with clinicians across hospitals, orthopedic clinics, and physiotherapy centers to capture end-user preferences, procedural workflows, and adoption barriers. These interviews provided context for how device features translate into operational value in real-world settings.

Complementing clinical and end-user inputs, vendor landscape analysis examined product portfolios, service offerings, and go-to-market approaches to understand competitive differentiation. Supply chain and policy analyses evaluated the implications of component sourcing, manufacturing footprints, and tariff exposure. Throughout the process, triangulation techniques were applied to reconcile disparate inputs and validate conclusions, ensuring that recommendations reflect convergent evidence rather than isolated data points.

Finally, sensitivity checks and peer reviews with external clinical advisors helped refine interpretations and prioritize insights that are most actionable for commercial and clinical leaders. This methodology produces a balanced synthesis of academic rigor and practical relevance, equipping stakeholders to make informed decisions about product development, market entry, and clinical strategy.

Synthesis of strategic imperatives showing how aligned product design, evidence generation, and commercial agility will determine long-term adoption success

In sum, extracorporeal shock wave therapy stands at an inflection point where clinical diversification, design innovation, and shifting procurement behaviors converge to create meaningful opportunities and practical challenges. Success will favor organizations that pair technical excellence with a pragmatic understanding of end-user workflows and regional regulatory realities. Companies that build credible real-world evidence, design modular platforms suited to multiple indications, and offer flexible commercial terms will be best positioned to accelerate adoption across hospitals, orthopedic clinics, and physiotherapy centers.

At the same time, external pressures such as tariff changes and evolving payer expectations necessitate proactive supply chain planning and stronger health economics evidence. Decision-makers must therefore integrate clinical development, manufacturing strategy, and commercial planning into a cohesive roadmap to mitigate risk and capture emerging demand. By aligning product features with operational needs and investing in outcomes measurement, stakeholders can demonstrate value to clinicians, patients, and payers alike.

Ultimately, the pathway to broader integration of shock wave therapy into standard care rests on translating clinical promise into reproducible, documented benefit within everyday practice. Organizations that achieve this translation will secure meaningful clinical and commercial returns while improving patient access to less invasive therapeutic options.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Extracorporeal Shock Wave Therapy Device Market, by Device Type

  • 8.1. Focused
  • 8.2. Radial

9. Extracorporeal Shock Wave Therapy Device Market, by Application

  • 9.1. Aesthetic
    • 9.1.1. Cellulite Reduction
    • 9.1.2. Scar Treatment
  • 9.2. Cardiology
    • 9.2.1. Myocardial Ischemia
    • 9.2.2. Refractory Angina
  • 9.3. Orthopedic
    • 9.3.1. Plantar Fasciitis
    • 9.3.2. Rotator Cuff Injury
    • 9.3.3. Tennis Elbow
  • 9.4. Urology
    • 9.4.1. Erectile Dysfunction
    • 9.4.2. Kidney Stone Treatment

10. Extracorporeal Shock Wave Therapy Device Market, by End User

  • 10.1. Hospital
  • 10.2. Orthopedic Clinic
  • 10.3. Physiotherapy Center

11. Extracorporeal Shock Wave Therapy Device Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Extracorporeal Shock Wave Therapy Device Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Extracorporeal Shock Wave Therapy Device Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Extracorporeal Shock Wave Therapy Device Market

15. China Extracorporeal Shock Wave Therapy Device Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. BTL Industries
  • 16.6. Dornier MedTech
  • 16.7. EMS Electro Medical Systems
  • 16.8. Guangzhou Longest Science & Technology
  • 16.9. Gymna
  • 16.10. Inceler Medikal
  • 16.11. LIKAMED GmbH
  • 16.12. MTS Medical
  • 16.13. Richard Wolf GmbH
  • 16.14. Storz Medical AG
  • 16.15. Tissue Regeneration Technologies
  • 16.16. Zimmer MedizinSysteme

LIST OF FIGURES

  • FIGURE 1. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY FOCUSED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY FOCUSED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY FOCUSED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY RADIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY RADIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY RADIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CELLULITE REDUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CELLULITE REDUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CELLULITE REDUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY SCAR TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY SCAR TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY SCAR TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY MYOCARDIAL ISCHEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY MYOCARDIAL ISCHEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY MYOCARDIAL ISCHEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY REFRACTORY ANGINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY REFRACTORY ANGINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY REFRACTORY ANGINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY PLANTAR FASCIITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY PLANTAR FASCIITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY PLANTAR FASCIITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ROTATOR CUFF INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ROTATOR CUFF INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ROTATOR CUFF INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY TENNIS ELBOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY TENNIS ELBOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY TENNIS ELBOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ERECTILE DYSFUNCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ERECTILE DYSFUNCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ERECTILE DYSFUNCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY KIDNEY STONE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY KIDNEY STONE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY KIDNEY STONE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY PHYSIOTHERAPY CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY PHYSIOTHERAPY CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY PHYSIOTHERAPY CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GCC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. GCC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. GCC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 141. GCC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. GCC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 143. GCC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. GCC EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. G7 EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. G7 EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. G7 EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 165. G7 EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. G7 EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 167. G7 EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. G7 EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. NATO EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. NATO EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. NATO EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. NATO EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 173. NATO EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. NATO EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 175. NATO EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. NATO EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY AESTHETIC, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY ORTHOPEDIC, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY UROLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA EXTRACORPOREAL SHOCK WAVE THERAPY DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)